Skip to content
Holt

Semaglutide vs Tirzepatide — How They Differ and What Trials Show

Semaglutide vs tirzepatide — one hormone target or two, the brands behind each, and what the SURPASS-2 and SURMOUNT-5 head-to-head trials found.

Written by Holt Editorial Team
Semaglutide and tirzepatide at a glance, from FDA labels and head-to-head trials
SemaglutideTirzepatide
Receptor targetsGLP-1GIP and GLP-1
US brandsOzempic (type 2 diabetes), Wegovy (weight, heart risk, MASH)Mounjaro (type 2 diabetes), Zepbound (weight, sleep apnea)
How it is takenWeekly injection; Wegovy also as a daily tabletWeekly injection only
Approximate half-lifeAbout 1 weekAbout 5 days
SURPASS-2 HbA1c change, 40 weeks−1.86 points (1 mg)−2.01 to −2.30 points (5–15 mg)
SURMOUNT-5 weight change, 72 weeks−13.7% (1.7 or 2.4 mg)−20.2% (10 or 15 mg)
Most common side effectsNausea, diarrhea, vomiting, constipation, stomach painNausea, diarrhea, vomiting, constipation, indigestion, stomach pain

Worth remembering

  • Semaglutide targets one receptor (GLP-1); tirzepatide targets two (GIP and GLP-1).
  • In SURMOUNT-5, average weight change at 72 weeks was −20.2% with tirzepatide and −13.7% with semaglutide.
  • In SURPASS-2, tirzepatide lowered HbA1c more than semaglutide 1 mg at all three doses tested.
  • Stomach side effects were the most common for both and mostly happened during dose increases.
  • Trial averages don't predict an individual result, and any switch is a prescriber's decision.

Your prescriber mentions both names in the same breath — "we could try semaglutide, or tirzepatide" — and you leave the appointment unsure what actually separates them. Brand names make it more confusing still: four of them, two molecules. This page sets the brands aside and compares the medicines themselves.

What is the real difference between the two molecules?

Both are weekly injections that copy gut hormones involved in appetite and blood sugar. The difference is how many hormone receptors they act on.

Semaglutide is a GLP-1 receptor agonist. Tirzepatide is a GIP receptor and GLP-1 receptor agonist — it activates both. The Zepbound label notes that GLP-1 is a known regulator of appetite, and that animal studies suggest GIP may add to that effect.

Each molecule is sold under two brands with different approvals. Semaglutide is Ozempic for type 2 diabetes and Wegovy for weight, heart risk reduction and a form of fatty liver disease called MASH. Tirzepatide is Mounjaro for type 2 diabetes and Zepbound for weight and obstructive sleep apnea.

What did the head-to-head trials find?

Two large trials have compared them directly. Both were funded by Lilly, which makes tirzepatide, and both were open-label, meaning participants knew which medicine they were taking.

SURPASS-2 (type 2 diabetes, 40 weeks). 1,879 adults on metformin were randomized to tirzepatide 5, 10 or 15 mg or semaglutide 1 mg. Average HbA1c fell by 2.01, 2.24 and 2.30 percentage points on the three tirzepatide doses, and by 1.86 on semaglutide. Weight reductions were also larger with tirzepatide, by an estimated 1.9, 3.6 and 5.5 kg more than semaglutide.

SURMOUNT-5 (obesity without diabetes, 72 weeks). 751 adults were randomized to the highest dose they could tolerate of tirzepatide (10 or 15 mg) or semaglutide (1.7 or 2.4 mg). Average weight change was −20.2% with tirzepatide and −13.7% with semaglutide. Waist circumference fell by an average of 18.4 cm and 13.0 cm.

These results describe averages across hundreds of people. Within each group, some people lost much more and some much less, and a trial cannot tell you which group you would fall into.

Neither trial was designed to study switching from one medicine to the other, and SURMOUNT-5 did not include semaglutide's newer 7.2 mg Wegovy dose. If you are weighing a change, those gaps are worth raising with your prescriber.

How do side effects compare?

For both medicines, the most common side effects are stomach-related, and most happen while the dose is being increased.

In SURPASS-2, nausea was reported by 17% to 22% on tirzepatide and 18% on semaglutide; diarrhea by 13% to 16% and 12%; vomiting by 6% to 10% and 8%. In SURMOUNT-5, the authors reported that gastrointestinal events were the most common in both groups and were mostly mild to moderate.

The warnings on all four labels look very similar, including a boxed warning about thyroid C-cell tumors seen in rodents.

Are there practical differences day to day?

A few, and they are worth knowing before you set up reminders.

  • Half-life. The Wegovy label puts semaglutide's half-life at about a week; the Zepbound label puts tirzepatide's at about 5 days.
  • Missed doses. The rules differ by brand. Mounjaro and Zepbound allow a missed dose within 4 days. Ozempic allows 5 days. Wegovy injection uses a different rule: take it if the next dose is more than 2 days away.
  • Forms. Semaglutide is also available as a daily tablet under the Wegovy brand. Tirzepatide comes in pens and vials, but no tablet.

What we'd track

Whichever molecule you end up on, these are the notes we would keep.

  1. Brand, dose and shot day. The missed-dose rule depends on the brand, so the log should say which one.
  2. Side effects against dose steps. It shows whether symptoms settle the way the labels describe.
  3. Weight trend, weekly. A gentle line is more honest than daily numbers.
  4. Meals and protein. Appetite often drops on both.
  5. The date of any change. New medicine, new dose, new form — so you and your prescriber can compare fairly.

Holt handles shots or pills, reminders, side effects, meals, water and weight on your iPhone, with Apple Health sync and a report for appointments. It is free to download, with an optional subscription.

Track either medicine in Holt

See it in Holt

Real screens from the app — the same places you’ll log, review and share.

  • Side effects, by severity
    Side effects, by severity

Frequently asked questions

Is tirzepatide stronger than semaglutide?

In the two head-to-head trials, tirzepatide led to larger average reductions in weight and HbA1c. That describes groups of people over 40 or 72 weeks, not what will happen for you, and it does not account for cost, coverage or how you tolerate each medicine.

Can I switch from semaglutide to tirzepatide?

That is a question for your prescriber. The labels don't give a conversion between the two, and neither SURPASS-2 nor SURMOUNT-5 studied switching.

Is there a semaglutide pill?

Yes. The Wegovy label now includes once-daily semaglutide tablets for weight reduction and cardiovascular risk reduction in adults. Tirzepatide is only available as a weekly injection.

Do they have the same warnings?

Largely, yes. Both carry a boxed warning about thyroid C-cell tumors seen in rodents, and both labels warn about pancreatitis, gallbladder disease, severe stomach side effects, kidney injury from dehydration, allergic reactions and aspiration during anesthesia.

Sources

  1. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5) — New England Journal of Medicine
  2. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2) — New England Journal of Medicine
  3. Wegovy (semaglutide) injection and tablets — Prescribing Information — U.S. Food and Drug Administration
  4. Ozempic (semaglutide) injection — Prescribing Information — U.S. Food and Drug Administration
  5. Zepbound (tirzepatide) injection — Prescribing Information — U.S. Food and Drug Administration
  6. Mounjaro (tirzepatide) injection — Prescribing Information — U.S. Food and Drug Administration